The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Inactivated Influenza Vaccine Market In 2026, And How Will Its Value Evolve By 2030?
The inactivated influenza vaccine market has experienced substantial growth over recent years. Forecasts predict its expansion from $7.14 billion in 2025 to $7.72 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. The upward trend witnessed historically stems from factors including a rise in the occurrence of seasonal influenza, the broadening of immunization initiatives, heightened public understanding of preventive healthcare, the presence of egg-based vaccine production, and the proliferation of public health programs.
The inactivated influenza vaccine market size is expected to show robust growth in the coming years. It is projected to reach $10.55 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.1%. This projected growth can be attributed to an increased focus on preparedness for pandemics, a rise in investments towards cell-based and recombinant vaccines, the broadening of immunization coverage for adults and elderly populations, an increase in government procurement of vaccines, and ongoing innovation in vaccine manufacturing technologies. Significant trends for the forecast period include the increasing adoption of quadrivalent influenza vaccines, a heightened focus on high-dose and adjuvanted vaccines, the expansion of seasonal vaccination programs, a growing emphasis on optimizing cold-chain processes, and an enhanced focus on the scalability of vaccine manufacturing.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24251&type=smp
What Key Factors Are Affecting The Inactivated Influenza Vaccine Market Demand?
The anticipated growth of the inactivated influenza vaccine market is significantly propelled by the increasing government vaccination programs. These programs are expanding because of heightened public health awareness among populations, which, in turn, boosts the demand for immunization services and encourages governments to improve vaccine accessibility and outreach efforts. Government vaccination initiatives streamline the delivery of inactivated influenza vaccines by providing free or subsidized access to high-risk individuals, thereby ensuring equitable immunization coverage and mitigating the impact of seasonal influenza. A relevant instance is the National Health Service, a UK-based government agency, which initiated an NHS vaccine strategy in December 2023 focused on immunization goals, including community-based vaccination services for underserved and marginalized communities. Therefore, the proliferation of government vaccination programs is a primary driver for the inactivated influenza vaccine market’s growth.
Which Segments Define The Inactivated Influenza Vaccine Market Segment Structure?
The inactivated influenza vaccine market covered in this report is segmented –
1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV), Quadrivalent Inactivated Influenza Vaccine (QIIV)
2) By Application: Children, Adolescence, Adults, Elderly
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Clinics
4) By End-User: Healthcare Providers, Individuals, Government Organizations, Pharmaceutical Companies
Subsegments:
1) Trivalent Inactivated Influenza Vaccine (TIIV): Egg-based Trivalent Inactivated Influenza Vaccine, Cell-based Trivalent Inactivated Influenza Vaccine, Adjuvanted Trivalent Inactivated Influenza Vaccine, High-dose Trivalent Inactivated Influenza Vaccine
2) Quadrivalent Inactivated Influenza Vaccine (QIIV): Egg-based Quadrivalent Inactivated Influenza Vaccine, Cell-based Quadrivalent Inactivated Influenza Vaccine, Adjuvanted Quadrivalent Inactivated Influenza Vaccine, Recombinant Quadrivalent Inactivated Influenza Vaccine, Pediatric Quadrivalent Inactivated Influenza Vaccine
What Trends Are Influencing Changes In The Inactivated Influenza Vaccine Market?
Major companies operating in the inactivated influenza vaccine market are intensifying their efforts to develop quadrivalent inactivated influenza vaccines, which are flu shots providing more extensive protection against four distinct strains of the influenza virus. For example, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, unveiled VaxiFlu-4. This quadrivalent inactivated influenza vaccine is engineered to deliver seasonal defense against four new virus strains. VaxiFlu-4 offers enhanced coverage by incorporating both influenza A and B strains, consequently lowering the potential for vaccine mismatch. The vaccine aims to manage seasonal flu outbreaks by stimulating an improved immune response, adapted specifically to regional epidemiological patterns.
Who Are The Established Players Within The Inactivated Influenza Vaccine Market?
Major companies operating in the inactivated influenza vaccine market are Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Viatris Inc., Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Hualan Biological Bacterin Co. Ltd., Changchun Biological Products Co. Ltd., Dalian Aleph Biomedical Co. Ltd., Jiangsu GDK Biotechnology Co. Ltd., KM Biologics Co. Ltd., JoinHub Pharma, Seqirus (CSL Influenza Division), Serum Institute of India Pvt. Ltd., Biological E. Limited, Shenzhen Sanofi Pasteur Biologicals Co. Ltd., Beijing Tiantan Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Sinopharm CNBG, Takeda Pharmaceutical Company Limited, Pfizer
Get The Full Inactivated Influenza Vaccine Market Report:
https://www.thebusinessresearchcompany.com/report/inactivated-influenza-vaccine-global-market-report
Which Region Dominates The Inactivated Influenza Vaccine Market By Market Share?
North America was the largest region in the inactivated influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Inactivated Influenza Vaccine Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=24251&type=smp
Browse Through More Reports Similar to the Global Inactivated Influenza Vaccine Market 2026, By The Business Research Company
Ultraviolet Analyzer Market Report 2026
https://www.thebusinessresearchcompany.com/report/ultraviolet-analyzer-global-market-report
Molecular Spectroscopy Market Report 2026
https://www.thebusinessresearchcompany.com/report/molecular-spectroscopy-global-market-report
Process Spectroscopy Market Report 2026
https://www.thebusinessresearchcompany.com/report/process-spectroscopy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model